Trials / Completed
CompletedNCT00366600
Study Evaluating HKI-272 Administered to Healthy Subjects
Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HKI-272 Administered Orally to Healthy Subjects.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 56 (actual)
- Sponsor
- Puma Biotechnology, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
Safety and tolerability of HKI-272 in healthy subjects; the influence of food intake on the same.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | neratinib | HKI-272 |
Timeline
- Start date
- 2006-07-01
- Primary completion
- 2006-12-01
- Completion
- 2006-12-01
- First posted
- 2006-08-21
- Last updated
- 2017-09-11
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00366600. Inclusion in this directory is not an endorsement.